Pfizer (PFE) Income from Non-Controlling Interests (2009 - 2026)

Pfizer (PFE) has reported Income from Non-Controlling Interests for 18 consecutive years, with $10.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Non-Controlling Interests fell 44.44% year-over-year to $10.0 million in Q2 2026; TTM through Jun 2026 was $35.0 million, a 35.19% decrease from a year earlier, with the FY2025 full-year figure at $41.0 million, up 32.26% from the prior year.
• Income from Non-Controlling Interests was $10.0 million for Q2 2026 at Pfizer, up from $8.0 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $23.0 million in Q3 2024 and troughed at $6.0 million in Q2 2022.
• A 5-year average of $10.1 million and a median of $8.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests slumped 76.92% in 2022 and soared 157.14% in 2025, its largest moves.
• Over 5 years, Income from Non-Controlling Interests stood at $6.0 million in 2022, then surged by 50.0% to $9.0 million in 2023, then surged by 155.56% to $23.0 million in 2024, then sank by 65.22% to $8.0 million in 2025, then gained by 25.0% to $10.0 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at $10.0 million (Q2 2026), $8.0 million (Q1 2026), and $8.0 million (Q4 2025), per Business Quant data.